Journals / MN Kardiyoloji / 2000 / Cilt: 7 - Sayı: 4

Levels of C reactive protein, fibrinogen and antithrombin III in coronary artery disease

Koroner arter hastalığında C reaktif protein, fibrinojen ve antitrombin III düzeyleri

Pages
295–298
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

RESULTS: As a result we could say that levels of C-reactive protein and fibrinogen may indicate the presence of coronary heart disease and effected by smoking which is an important risk factor for the coronary heart disease, but levels of antithrombin III not differ between two groups and has no benefit in predicting the presence of coronary heart disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: In different trials changes in the levels of fibrinogen, C-reactive protein and antithrombin III were reported in the patients with coronary artery disease.
📊
Key Findings & Data:MATERIALS AND METHODS: In our trial levels of fibrinogen, C-reactive protein and antithrombin III were determined in 150 patients with documented coronary artery disease (50 female, 57.6+10.0 years old), and 50 healthy volunteer (16 female, 58.0+9.8 years old, p>0.05).
💡
Conclusion & Impact:RESULTS: As a result we could say that levels of C-reactive protein and fibrinogen may indicate the presence of coronary heart disease and effected by smoking which is an important risk factor for the coronary heart disease, but levels of antithrombin III not differ between two groups and has no benefit in predicting the presence of coronary heart disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:C-reaktif protein · Antitrombin III · Sigara içme

Abstract

AIM: In different trials changes in the levels of fibrinogen, C-reactive protein and antithrombin III were reported in the patients with coronary artery disease. MATERIALS AND METHODS: In our trial levels of fibrinogen, C-reactive protein and antithrombin III were determined in 150 patients with documented coronary artery disease (50 female, 57.6+10.0 years old), and 50 healthy volunteer (16 female, 58.0+9.8 years old, p>0.05). RESULTS: In patient group C- reactive protein (p =0.001) and fibrinogen (p=0.001) levels were significantly higher than patient group. But levels of antithrombin III showed no difference between two groups (p>0.05). C-reactive protein (r=0.30, p= 0.005) and fibrinogen (r=0.35, p=0.004) levels showed a positive relation with smoking. Smoking ratios were similar for both groups (40% for both). RESULTS: As a result we could say that levels of C-reactive protein and fibrinogen may indicate the presence of coronary heart disease and effected by smoking which is an important risk factor for the coronary heart disease, but levels of antithrombin III not differ between two groups and has no benefit in predicting the presence of coronary heart disease.

Özet

AMAÇ: Değişik çalışmalarda koroner arter hastalığında kan C-reaktif protein, fibrinojen ve antitrombin III düzeyleri çalışılmış ve değişik sonuçlar elde edilmiştir. Bu prospektif kontrollü çalışmada biz de koroner arter hastalığı varlığında kan C-reaktif protein, fibrinojen ve antitrombin III düzeylerini çalıştık. GEREÇ VE YÖNTEM: Çalışmada koroner arter hastalığı dokümente edilmiş 150 (50 kadın, 57.6±10.0 yaş) ve sağlıklı gönüllü 50 (16 kadın, 58.0±9.8 yaş, p>0.05) olguda kan C-reaktif protein, fibrinojen ve antitrombin III düzeylerine bakıldı. BULGULAR: Hasta grubunda C-reaktif protein (p=0.001) ve fibrinojen (p=0.001) düzeyleri kontrol grubuna göre belirgin olarak yüksekti. Fakat antitrombin III düzeylerinde belirgin farklılık yoktu (p>0.05). C-reaktif protein (r=0.30, p=0.005) ve fibrinojen (r=0.35, p=0.004) düzeyleri sigara kullanımı ile belirgin pozitif bağlantı gösteriyordu. Sigara kullanım oranları her iki grupta da benzerdi (iki grupta da %40). SONUÇ: Sonuç olarak kan C reaktif protein ve fibrinojen düzeylerinin koroner arter hastalığı varlığı hakkında bilgi verebileceğini ve koroner arter hastalığı risk faktörlerinden biri olan sigara kullanımı ile düzeylerinin arttığını, .antitrombin III'ün ise koroner arter hastalığı ve kontrol olgularında farklılık göstermediğini söyleyebiliriz.

🔖

Cite This Article

KAFTAN, H. A., ALPSOY, Ş., KAFTAN, O. (2000). Levels of C reactive protein, fibrinogen and antithrombin III in coronary artery disease. MN Kardiyoloji, Cilt: 7 - Sayı: 4, 295–298. https://ajindex.com/articles/297848

References (3)

  1. Ross. T. The pathogeneşis of atherosclerosis: a perspective for the 1990s: Nature 1993; 362:801 Alexander RW. Inflammation and coronary artery disease (editorial). N Engl J Med 1994; 331:468: Ernest E. Fibrinogen as a cardiovascular risk factor: interrelationship with infections and inflammation. Eur Heart J 1994; 14:82. Heinrich J, Schulte H, Schönfeld R, Köhler E, Assman G. Association of variables of coagulation fibrinolysis and acute phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemostas 1995; 73:374-378
  2. Kaftan HA, Kaftan O, Kılıç M. Markers of chronic infection and inflammation: Are they important in cases with chronic coronary heart disease. Jpn Heart J 1999; 40:275. Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van de Loo JCW. Hemostatic facrors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332:635. Ernst E. Fibrinogen: A "new" cardiovascular risk factor. Wien Med Wochenschr1991; 141:375. Bernd Eber, Schumacher M. Fibrinogen: Its role in hemostatic regulation in atherosclerosis. Seminars in Thrombosis and Hemostasis 1993; 19(2): 104. Seegers WH: Use and regulation of blood clotting mechanisms, Blood Clotting Enzymology. Edited by Seegers. New York Academic Press, 1971.
  3. Knudsen JB, Gormsen J, Skagen K, Amtorp O: Changes in platelet function, coagulation and fibrinolysis in uncomplicated cases of acute myocardial infarction. Thromb Haemostas 1979; 42:1513. Mustard JF, Packham MA. The role of blood and platelets in atherosclerosis and the complications of atherosclerosis. Thromb Diath Haemorrh 1975; 33:444. Yue RH, Gertler MM, Starr T, Kautrouby R. Alterations of plasma antithrombin III levels in ischemic heart disease. Thromb Haemostas 1976; 35:598. O'Brien JR, Etherington MD, Jamieson S, Lawford P, Lincoln SV, Alkajersig N. Blood changes in atherosclerosis and lung after myocardial infarction and venous thrombosis. Thromb Diath Haemorrh 1975; 34:483. Banerjee RN, Sahni AL, Kumar V, Arya M. Antithrombin III deficiency in maturity onset diabetes mellitus and atherosclerosis. Thromb Diath Haemorrh 1974; 31:339. Innerfield I, Goldfischer JD, Reicher-Reiss J, Greenberg J. Serum antithrombin in coronary artery disease. Am J Clin Pathol 1976; 65:64. Hedner U, Nilsson IM. Antithrombin in a clinical material. Thromb Res 1973; 3:631. Cella G, Russo R. Heparin neutralizing activity (HNA) and antithrombin III in coronary artery disease.